中国与欧洲的血液系统恶性肿瘤的流行病学差异.pdfVIP

Correspondence are faced with many drug–drug relation of tyrosine-kinase inhibitors. 0·6 Leukaemia 3 Several clinical trials are ongoing. interactions in clinical practice. As Multiple myeloma o i 0·5 Non-Hodgkin lymphoma therapeutic drug monitoring for When ranges for therapeutic target t a r e Hodgkin’s lymphoma most tyrosine-kinase inhibitors is concentrations have been defi ned, c n 0·4